Immediate ART in Subjects With Opportunistic Diseases

Overview

The aim of this study is to compare the clinical response and mortality rate by an opportunistic disease in HIV-infected individuals who start immediate versus conventional antiretroviral therapy. Immediate ART (iART) is defined as starting antiretroviral therapy in the first 48 hours after the hospitalization. Conventional ART (cART) is defined as starting antiretroviral therapy once the opportunistic infection is under control at the discretion of infectious disease specialist.

Full Title of Study: “Impact of the Timing of Antiretroviral Therapy Initiation (Immediate Versus Early) on the Mortality Rate of HIV/AIDS Patients Hospitalized With an Opportunistic Disease”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: April 30, 2024

Detailed Description

Sample size was calculated using formula, of difference in proportions formula using a beta of 0.1, alpha of 0.05 and an expected difference in mortality of 20%, The sample size is 225 subjects in each group. Informed consent will be obtained. Patients will be allocated to each group (iART or cART) after randomization stratified by the CD4+ T cell count (less or more than 50 cells/mm3). Plasma viral load and CD4+ T cell count will be measured at study entry and at weeks 2, 4, 12, 24 and 48 after ART initiation. Clinical outcomes will be: mortality at 4, 12, 24, and 48 weeks, length of hospitalization (measured in days), clinical and microbiological cure of the opportunistic disease, incidence and severity of immune reconstitution of inflammatory syndrome (IRIS), and adverse drug reactions and interactions. Once 50% of the sample size has completed 30 days of follow-up, a preliminary analysis will be conducted to assess safety and efficacy of iART; if differences in the mortality are observed, the study will be terminated.

Interventions

  • Other: iART
    • After group assignment, ART will be started within the first 48 hours after admission to the hospital. ART regimen will be decided according to each subject´s the clinical characteristics
  • Other: cART
    • After group assignment, ART is started at the discretion of the attending physician. ART regimen will be decided according to each subject´s the clinical characteristics

Arms, Groups and Cohorts

  • Experimental: Group A Immediate treatment (iART)
    • Other: time to start the ART within 48 hours of admission to hospitalization
  • Active Comparator: Group B Conventional treatment (cART)
    • Other: time to start the ART, after the opportunistic disease has been controlled, at the discretion of infectious disease specialist.

Clinical Trial Outcome Measures

Primary Measures

  • Mortality
    • Time Frame: 30 days
    • Compare mortality rates betweeno two groups according to the timing of ART initiation: immediate antiretroviral therapy (iART) versus conventional antiretroviral therapy (cART)

Secondary Measures

  • Assess survival rates
    • Time Frame: 90 days since starting antiretroviral therapy (ART)
    • Compare the survival rate of HIV-infected patients on immediate antiretroviral therapy (iART) versus conventional antiretroviral therapy (cART)
  • Assess survival rates
    • Time Frame: 180 days since starting antiretroviral therapy (ART)
    • Compare the survival rate of HIV-infected patients on immediate antiretroviral therapy (iART) versus conventional antiretroviral therapy (cART)
  • Assess survival rates
    • Time Frame: 360 days since starting antiretroviral therapy (ART)
    • Compare the survival rate of HIV-infected patients on immediate antiretroviral therapy (iART) versus conventional antiretroviral therapy (cART)
  • Length of stay
    • Time Frame: 1 year
    • Compare length of hospitalization between both groups
  • Asses survival rates by the CD4 count
    • Time Frame: 90 days
    • Compare the survival rate of HIV-infected patients on immediate antiretroviral therapy (iART) versus conventional antiretroviral therapy (cART) stratified by CD4+ T cell count at study entry
  • Asses survival rates by the CD4 count
    • Time Frame: 180 days
    • Compare the survival rate of HIV-infected patients on immediate antiretroviral therapy (iART) versus conventional antiretroviral therapy (cART) stratified by CD4+ T cell count at study entry
  • Asses survival rates by the CD4 count
    • Time Frame: 360 days
    • Compare the survival rate of HIV-infected patients on immediate antiretroviral therapy (iART) versus conventional antiretroviral therapy (cART) stratified by CD4+ T cell count at study entry
  • Viral load
    • Time Frame: 90 days
    • Measure the baseline plasma viral load and evaluate its dynamics after ART initiation in both groups
  • Viral load
    • Time Frame: 180 days
    • Measure the baseline plasma viral load and evaluate its dynamics after ART initiation in both groups
  • Viral load
    • Time Frame: 360 days
    • Measure the baseline plasma viral load and evaluate its dynamics after ART initiation in both groups
  • CD4 T cell counts
    • Time Frame: 90 days
    • Measure CD4+ T cell counts, and evaluate its dynamics after ART initiation in both groups
  • CD4 T cell counts
    • Time Frame: 180 days
    • Measure CD4+ T cell counts, and evaluate its dynamics after ART initiation in both groups
  • CD4 T cell counts
    • Time Frame: 360 days
    • Measure CD4+ T cell counts, and evaluate its dynamics after ART initiation in both groups
  • IRIS
    • Time Frame: 48 weeks
    • Determine the incidence and severity of IRIS. Severity will be classified as mild or life threatening
  • Adverse reactions
    • Time Frame: 48 weeks
    • Describe ART-related adverse events, and drug interactions

Participating in This Clinical Trial

Inclusion Criteria

  • Over 18 years old – Time from admission to study entry: less than 48 hours – Confirmed HIV diagnosis or high probability of HIV infection based on a positive HIV rapid test – Having an opportunistic disease – Subjects must be naïve to ART or have failed their first or second ART regimen or must have abandoned ART for more than 3 months Exclusion Criteria:

  • Meningitis due to Cryptococcus spp. or for M. tuberculosis – Pregnancy

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 60 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Gustavo Reyes-Teran
  • Provider of Information About this Clinical Study
    • Sponsor-Investigator: Gustavo Reyes-Teran, Principal Investigator – Centro de Investigación en. Enfermedades Infecciosas, Mexico
  • Overall Official(s)
    • GUSTAVO MD REYES-TERÁN, M.D., Principal Investigator, Instituto Nacional de Enfermedades Respiratorias
  • Overall Contact(s)
    • GUSTAVO MD REYES-TERÁN, M.D., 56667985, gustavo.reyesteran@gmail.com

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.